The new price transparency tool to compare reimbursement rates.

The FDA has approved inebilizumab-cdon (Uplizna, Amgen) for adults with anti-acetylcholine receptor and anti-muscle specific tyrosine kinase antibody positive generalized myasthenia gravis, according ...